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Objective: To evaluate the ovarian reserve function in female patients with metabolic syndrome (MetS).
Methods: This study evaluated 136 subjects, 67 with MetS and 69 controls. Subjects were divided into three age
groups. Group I included 49 subjects aged 20–29 years, 22 with MetS and 27 controls; group II included 45 subjects
aged 30–39 years, 22 with MetS and 23 controls; and group III included 42 subjects aged 40–49 years, 23 with MetS
and 19 controls. Demographic characteristics, anthropometrics, blood biochemistry, and gonadotrophic hormones
were compared as total ovarian volume and antral follicle count on ovarian transvaginal ultrasonography.
Results: Serum levels of FSH, LH, E2 and progesterone were similar in the MetS and control groups, while
testosterone levels were significantly higher in MetS patients than controls, both in the overall population (p =
0.024) and in those aged 20–29 years (p = 0.018). Total ovarian volume was significantly lower in MetS patients than
controls, in both the overall population (p = 0.003) and those aged 20–29 years (p = 0.018), while antral follicle
counts were similar. Ovarian volume correlated positively with antral follicle count (AFC) (r = 0.37; p < 0.001) and
negatively with age (r = 0.34; p < 0.001) and FSH concentration (r = 0.21; p = 0.013). AFC was negatively correlated
with age (r = 0.36; p < 0.001).
Conclusion: Ovarian reserve function is significantly lower in MetS patients than in healthy control subjects,
particularly in women aged 20–29 years.
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Female fertility, by spontaneous conception or assisted
reproductive techniques, decreases significantly with age,
a reduction that may be due to the reduction in the
number of primordial follicles over time [1-3]. Ovarian
reserve is a measure of the reproductive potential of a
woman in relation to primordial follicle count and oo-
cyte quality. Follicle response to stimulation and fertility
promoting medications is reduced in parallel to the reduc-
tion in ovarian reserve. Determinants of ovarian reserve
include basal FSH and inhibin B levels (4), estradiol and
LH concentrations, LH/FSH ratio, response to stimulation
with gonadotropin releasing hormone (GnRH), ovarian* Correspondence: calperuslu@yahoo.com
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unless otherwise stated.volume, total antral follicle count (AFC) and ovarian stro-
mal blood flow [4,5]. A meta-analysis found that AFC was
a better predictor of ovarian response than basal FSH level
[6], and several studies have shown that AFC, as deter-
mined by high-resolution transvaginal ultrasonography, is
a significant predictor of ovarian response [4-7].
Insulin resistance plays a central role in metabolic syn-
drome (MetS) [8,9]. Obesity has been associated with
multiple adverse reproductive outcomes in both males
and females [10], although the exact mechanisms are
largely unknown. The complexity of the human repro-
ductive system makes identification of the mechanisms
linking obesity and adverse reproductive functioning
challenging [11].
Despite MetS having a negative impact on fertility in
women of reproductive age, cross-sectional evidence sug-
gests that increased ovarian reserve is associated with aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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knowledge, however, the effect of MetS on ovarian func-
tions has not been previously investigated. Therefore the
present study was designed to evaluate ovarian reserve
function in female patients with MetS in Turkey in rela-
tion to healthy controls and among different age groups.Methods
Study population
The study included 136 subjects, comprising 67 pa-
tients with MetS and 69 healthy controls, who were
evaluated at the Department of Endocrinology and
Metabolic Diseases, Aksaray State Hospital, between
January and July 2013. Subjects were divided into
three groups by age. Group I consisted of 49 sub-
jects aged 20–29 years, including 22 MetS patients
and 27 controls; group II consisted of 45 subjects
aged 30–39 years, including 22 MetS patients and 23
controls; and group III consisted of 42 subjects aged
40–49 years, including 23 MetS patients and 19 con-
trols. Subjects were included if they had a history of
spontaneous pregnancy, regularly menstruated at
intervals of 21–35 days, had cycle length variations
of less than 4 days and had both ovaries. Subjects
were excluded if they had a history of chronic renal
or liver failure, autoimmune or connective tissue
disease, a known malignancy, a history of smoking,
known infertility, gynecological abnormalities such as
dysfunctional uterine bleeding or menorrhagia, a his-
tory of ovarian surgery, or if they had used a hormo-
nal preparation or dubious herbal product within the
3 months prior to enrollment.
Following a detailed explanation of the objectives and
protocol of the study, written informed consent was ob-
tained from each subject. The study was conducted in
accordance with the ethical principles stated in the Dec-
laration of Helsinki and was approved by the institu-
tional ethics committee of Aksaray State Hospital.Study parameters
Demographic and clinical characteristics were recorded
for each subject, including anthropometric factors, such
as weight, height, body mass index (BMI), waist circum-
ference, and waist-to-hip ratio (WHR). Blood biochemis-
try parameters included fasting blood glucose (FBG),
insulin, high density lipoprotein-cholesterol (HDL-C) and
triglyceride (TG) concentrations and homeostasis model
assessment-IR (HOMA-IR). Serum concentrations of go-
nadotrophic hormones were measured, including follicle
stimulating hormone (FSH), luteinizing hormone (LH), es-
tradiol (E2), progesterone, and testosterone. Total ovarian
volume (cm3) and AFC were determined by ovarian trans-
vaginal ultrasonography.Assessment of MetS
A diagnosis of MetS was based on the criteria of the Na-
tional Cholesterol Education Program (NCEP)-ATP III
and included three of the following five factors: (i) abdominal
obesity, defined as a waist circumference (WC) > 102 cm in
men and > 88 cm in women; (ii) serum TGs ≥ 150 mg/dl;
(iii) serum HDL< 40 mg/dl in men and < 50 mg/dl in
women; (iv) blood pressure > 130/85 mmHg; and (v) FBG>
110 mg/dl [13].
Assessment of insulin resistance
The estimate of insulin resistance by HOMA-IR score
was calculated with the formula fasting serum insulin
(lU/ml) × FBG (mmol/l)/22.5 as described by Matthews
and coworkers [14]. The cut-off value was taken as 2.7
for HOMA-IR [15].
Anthropometric measurements
Height, weight, and WC were measured by a designated
physician. WC was measured with a folding tape at the
natural waistline (the level of the umbilicus) in a hori-
zontal plane. BMI was calculated by dividing body
weight (kg) by the square of height (m), and WHR was
calculated by dividing waist by hip circumference.
Blood biochemistry analysis
Venous blood samples were taken from the antecubital
regions of all subjects between 08:00 am and 09:00 am
after an overnight fast of 8–12 hours. Serum FPG con-
centrations were measured by the hexokinase method.
Serum FSH, LH, total testosterone, E2, progesterone
and insulin were measured with specific electrochemilu-
minescence immunoassays (Elecsys 2010 Cobas, Roche
Diagnostics, Mannheim, Germany). Totalcholesterol,
HDL-C and TG concentrations were measured using en-
zymatic colorimetric assays by spectrophotometry (Abbott
Architect C16000).
Assessment of ovaries by transvaginal ultrasonography
Transvaginal ultrasonographic examinations, using a
Toshiba Aplio 500 device fitted with a 6-MHz transvagi-
nal probe, were scheduled for between the second and
fourth day of menstruation, the same day the blood sam-
ples were obtained. All ultrasonographic examinations
were performed by a previously designated and experi-
enced radiologist (N.C.) who was blinded to all patient
information. The length, width, and height of each ovary
were measured in the sagittal and coronal plains. Ovar-
ian volume was calculated using the ellipsoid formula
(length × width × height)/6. The number of antral folli-
cles <10 mm in each ovary was counted. Total ovarian
volume (right plus left ovarian volume) and total AFC in
the left and right ovaries were calculated.
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Statistical analysis was performed using SPSS for Win-
dows 17 software (SPSS Inc., Chicago. IL). Normality of
distribution of continuous variables was evaluated using
the Shapiro Wilk test. Means were compared using Stu-
dent’s t tests or Mann–Whitney U test, as appropriate.
Spearman’s rho test was used for correlation analysis of
factors in the MetS groups. A p value <0.05 was consid-
ered statistically significant.
Results
Demographic characteristics and anthropometric and
laboratory findings
In the overall population, mean ± SDBMI (36.1 ± 5.7 vs.
27.1 ± 4.8 kg/m2, p < 0.001), WC (106.0 ± 13.1 vs. 83.8 ±
12.3 cm, p < 0.001), and insulin (15.1 ± 5.9 vs. 10.1 ± 5.4
IU/ml, p < 0.001), FBG (94.8 ± 10.3 vs. 91.6 ± 8.5 mg/dl,
p = 0.049), and TG (159.6 ± 77.5 vs. 113.0 ± 41.3 mg/dl,
p < 0.001) concentrations were significantly higher, while
HDL-C concentrations (40.8 ± 10.8 vs. 49.7 ± 10.2 mg/dl,
p < 0.001) were significantly lower among patients with
MetS than in control subjects (Table 1). When grouped
by age (20–29, 30–39, and 40–49 years), mean BMI (p <
0.001 each), WC (p < 0.001 each), HOMA-IR (p = 0.002,
p = 0.005 and p = 0.02, respectively) and insulin concen-
trations (p = 0.002, p = 0.005 and p = 0.01, respectively)
were significantly higher in patients with MetS than in
control subjects.
Gonadal hormone concentrations
Serum concentrations of FSH, LH, E2 and progesterone
were similar in overall patients and controls, as well as
in each of the age groups (Table 2). Testosterone con-
centrations, however, were significantly higher in MetS
patients than in controls, both in the overall populationTable 1 Demographic characteristics, anthropometrics and labo
Study groups according to










(n = 23) v
Age (yr) 24.0 ± 5.1 23.9 ± 3.8 0.900 34.1 ± 3.1 33.7 ± 2.9 0
BMI (kg/m2) 34.1 ± 5.6 23.8 ± 4.4 <0.001 35.9 ± 5.8 28.1 ± 3.2 <
WC (cm) 110.8 ± 11.6 83.8 ± 11.0 <0.001 107.2 ± 14.4 86.3 ± 9.7 <
HOMA-IR 3.6 ± 1.7 2.2 ± 1.3 0.002 3.7 ± 1.8 2.2 ± 1.4
FBG (mg/dl) 92.7 ± 5.5 88.9 ± 6.8 0.043 97.2 ± 13.5 92.2 ± 9.0
TG (mg/dl) 135.2 ± 74.7 104.0 ± 28.8 0.052 169.0 ± 65.3 119.1 ± 32.7 0
HDL-C (mg/dl) 41.2 ± 12.4 51.3 ± 9.5 0.002 41.9 ± 12.2 48.0 ± 10.2 0
Insulin (IU/ml) 15.9 ± 7.3 10.1 ± 5.4 0.002 14.8 ± 5.5 9.8 ± 5.5 0
Data are shown as Mean (SD). BMI: Body mass index; FBG: fasting blood glucose; HD
TG: triglyceride; WC: waist circumference; WHR: waist to hip ratio.(0.2(0.1) vs. 0.2(0.1) ng/ml, p = 0.024) and in the 20–29
age group (0.3(0.1) vs. 0.2(0.1) ng/ml, p = 0.018).
Radiological findings
Total ovarian volume was significantly lower in MetS
patients than in controls, both in the overall population
(6.8 ± 2.4 vs. 8.2 ± 2.8 ng/ml, p = 0.003) and in the 20–29
age group (7.5 ± 2.8 vs. 9.5 ± 2.3 ng/ml, p = 0.018). AFCs
were similar in patient and control groups, both in the
overall population and the three age groups. Moreover,
AFC did not correlate with age, either in the patient or
control groups (p > 0.05 each).
Correlation of ovarian reserve function with clinical,
laboratory and radiological findings
Ovarian volume correlated positively with AFC (r = 0.37;
p < 0.001), while correlating negatively with age (r = 0.34;
p < 0.001) and FSH concentration (r = 0.21; p = 0.013).
AFC was correlated negatively with age (r = 0.36; p <
0.001).
Discussion
This study, the first to investigate ovarian reserve func-
tion in women with MetS, found that ovarian reserve, as
determined by ovarian volume, was significantly lower in
patients with MetS than in healthy controls, in particular
in women aged 20–29 years. Moreover, ovarian volume
was found to be positively correlated with AFC, and ovar-
ian volume and AFC were negatively correlated with age.
Ovarian reserve can be determined by measuring AFC
and ovarian volume by ultrasonography during the early
follicular phase. Although we found that ovarian volume
was significantly lower in MetS patients than in controls,
AFC tended to be lower and FSH concentrations higher
in the former, a finding consistent with the reverseratory findings in study groups
age Total (n = 136)















.700 42.5 ± 2.9 43.1 ± 2.8 0.48 33.7 ± 8.2 32.5 ± 8.5) 0.376
0.001 38.1 ± 5.2 30.5 ± 4.1 <0.001 36.1 ± 5.7 27.1 ± 4.8 <0.001
0.001 108.9 ± 13.9 91.6 ± 13.1 <0.001 106.0 ± 13.1 83.8 ± 12.3 <0.001
0.005 3.4 ± 1.3 2.4 ± 1.3 0.020 3.7 ± 1.6 2.3 ± 1.3 0.268
0.150 94.5 ± 10.3 94.5 ± 9.2 0.980 94.8 ± 10.3 91.6 ± 8.5 0.049
.002 173.8 ± 87.7 118.3 ± 61.1 0.020 159.6 ± 77.5 113.0 ± 41.3 <0.001
.080 39.4 ± 7.1 49.3 ± 11.2 0.001 40.8 ± 10.8 49.7 ± 10.2 <0.001
.005 14.5 ± 4.5 10.3 ± 5.6 0.010 15.1 ± 5.9 10.1 ± 5.4 <0.001
L-C: high density lipoprotein cholesterol; MetS: metabolic syndrome;
Table 2 Gonadal hormones and radiological findings in the study groups
Study groups according to age Total (n = 136)


























FSH (mIU/ml) 7.5 ± 8.5 5.9 ± 1.4 0.31 6.2 ± 2.4 6.3 ± 2.3 0.87 7.9 ± 3.4 8.0 ± 3.5 0.95 7.3 ± 5.4 6.6 ± 2.6 0.381
LH (mIU/ml) 5.7 ± 2.9 5.5 ± 2.1 0.77 5.6 ± 2.7 5.3 ± 2.4 0.72 6.3 ± 3.5 5.6 ± 2.3 0.46 5.92 ± 3.1 5.5 ± 2.2 0.380
FSH/LH 1.5 ± 1.7 1.2 ± 0.5 0.4 1.3 ± 0.6 1.4 ± 0.8 0.69 1.4 ± 0.5 1.5 ± 0.6 0.65 1.41 ± 1.1 1.34 ± 0.7 0.593
E2 (pg/ml) 35.8 ± 16.4 36.1 ± 14.9 0.94 35.3 ± 17.0 38.3 ± 15.0 0.53 41.4 ± 18.6 39.4 ± 13.1 0.7 37.6 ± 17.4 37.8 ± 14.4 0.940
Progesteron (ng/ml) 0.4 ± 0.2 0.8 ± 1.6 0.37 0.5 ± 0.8 0.6 ± 0.8 0.73 0.5 ± 0.8 0.4 ± 0.4 0.5 0.5 ± 0.7 0.6 ± 1.1 0.495
Testosteron (ng/ml) 0.3 ± 0.1 0.2 ± 0.1 0.018 0.2 ± 0.1 0.2 ± 0.1 0.17 0.2 ± 0.1 0.2 ± 0.1 0.57 0.2 ± 0.1 0.2 ± 0.1 0.024
Radiological findings
Total ovarian volume (cm3) 7.5 ± 2.8 9.3 ± 2.3 0.018 7.0 ± 2.0 8.5 ± 3.2 0.07 5.9 ± 2.2 6.1 ± 1.4 0.77 6.8 ± 2.4 8.2 ± 2.8 0.003
Total antral follicle count 24.7 ± 17.9 28.5 ± 11.9 0.37 24.1 ± 21.6 23.4 ± 14.1 0.89 12.7 ± 13.0 8.1 ± 5.5 0.152 20.4 ± 18.4 21.2 ± 14.1 0.77
Data are shown as Mean (SD). E2. Estradiol; FSH: Follicle stimulating hormone; LH: Luteinizing hormone; MetS: metabolic syndrome.
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less, due to the positive correlation between ovarian
volume with AFC and the negative correlations of both
with age in our study population, our findings suggest
that ovarian androgen production not only declines
with menopause but also with older age [16].
The present findings, showing a significant reduction
in ovarian volume in patients with MetS, are in agree-
ment with results showing delayed menarche and irregu-
lar menstruation in patients with type 1 diabetes [17]
and significant reductions in ovarian volume and AFC in
patients with type 2 diabetes aged 20–29 years [1], com-
pared with age-matched controls. In contrast, ovarian
volumes in subjects aged 20–39 and 40– 49 years were
similar in those with MetS and healthy controls. Type I
diabetes patients have also been shown to have a high
risk of premature menopause [18].
A previous study of Turkish women aged 16 to 40
years found that ovarian volumes were significantly
lower among patients with than without polycystic ovar-
ian syndrome (12.5 vs. 5.4 cm3) [19]. Another study in-
volving 62 infertile and 53 fertile women aged 35 to 45
years found that mean AFC counts and FSH levels were
similar, while ovarian volume was significantly lower in
infertile than in fertile women (1.8 vs. 6.1 cm3) [20].
Since ovarian volume is a parameter used in traditional
in vitro fertilization methods [21], age and ovarian vol-
ume were found to be negatively correlated with subject
age [22]. Ovarian volume and AFC both decreased with
age in our study population. A Brazilian study reported
that mean ovarian volume was 7.1 cm3 during the peri-
menopausal period, decreasing 0.2cm3 each year [23]. A
study in China of 31 healthy volunteers aged 22 to 42
years, found that AFC declined at a rate of 0.95 follicles/
year or 60% [24], while another study of infertile Chinesewomen showed that AFC declined 0.35 follicles/year or
3.8% [25,26].
Various mechanisms may be responsible for the reduc-
tion in ovarian reserve among diabetic women. Chronic
complications and prolonged hyperglycemia have been
reported to negatively affect ovarian reserve, with regular
blood glucose control suggested to improve fertility and
menstruation anomalies [17].
Polycystic ovarian reserve and diabetes prevalence was
reported to increase with increasing obesity, resulting in
reductions in oocyte quality [27]. Diabetes related in-
creases in menstruation anomalies and the risk of pre-
mature menopause were shown to be associated with
increased cardiovascular risks [28]. In agreement with
the significantly higher testosterone concentrations we
observed in MetS patients than in controls, a Chinese
study of 719 women with polycystic ovary syndrome and
685 healthy volunteers found that patients with polycys-
tic ovary syndrome and obesity had higher serum testos-
terone and fasting insulin levels, lower LH levels, and
enlarged ovarian follicles compared with control subjects
[24]. In many studies on patients undergoing invitro
fertilization procedures, increased BMI was found to
have a negative impact on ovarian reserve [29]. More-
over, inhibin B levels and AFC were significantly lower
in overweight patients [29]. Indeed, we found that ovar-
ian volume was greater in patients with BMI <30 kg/m2
than in subjects with higher BMI.
Although the impact of obesity on the female repro-
ductive system remains unclear, obesity is considered a
risk factor for poorer overall health, which, in turn, has
negative effects on reproduction, menstrual function,
ovulation, and GnRH regulation [30]. Obesity is also an
independent risk factor for PCOS and plays important
roles in the clinical, metabolic, and biochemical changes
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cantly higher BMI and waist circumference among pa-
tients with MetS and type II diabetes [1,32] accords with
thehigh prevalence of infertility and low chance of preg-
nancy of such patients, even using assisted reproductive
technologies [33].
In conclusion, we found that ovarian reserve was lower
in patients with MetS than in healthy control subjects,
especially in those aged 20–29 years. We also observed a
positive correlation between ovarian volume and AFC and
negative correlations of both with age. Since a greater
ovarian reserve has been associated with a healthier car-
diometabolic risk factor profile [12], future larger scale
studies are needed to clarify the role of obesity in the as-
sociation between MetS and ovarian reserve, along with
other likely determinants of this interaction.
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